Tau Phosphorylation is Impacted by Rare AKAP9 Mutations Associated with Alzheimer Disease in African Americans

Tsuneya Ikezu, Cidi Chen, Annina M. DeLeo, Ella Zeldich, Daniele Daniele Fallin, Nicholas M. Kanaan, Kathryn L. Lunetta, Carmela R. Abraham, Mark W. Logue, Lindsay A. Farrer

Research output: Contribution to journalArticle

Abstract

We studied the effect of two rare mutations (rs144662445 and rs149979685) in the A-kinase anchoring protein 9 (AKAP9) gene, previously associated with Alzheimer disease (AD) in African Americans (AA), on post-translational modifications of AD-related pathogenic molecules, amyloid precursor protein (APP) and microtubule-associated protein Tau using lymphoblastoid cell lines (LCLs) from 11 AA subjects with at least one AKAP9 mutation and 17 AA subjects lacking these mutations. LCLs were transduced by viral vectors expressing causative AD mutations in APP or human full-length wild type Tau. Cell lysates were analyzed for total APP, Aβ40, and total and T181 phospho-Tau (pTau). AKAP9 mutations had no effect on Aβ40/APP, but significantly increased pTau/Tau ratio in LCLs treated with phosphodiesterase-4 inhibitor rolipram, which activates protein kinase A. Proteomic analysis of Tau interactome revealed enrichment of RNA binding proteins and decrease of proteasomal molecules in rolipram-treated cells with AKAP9 mutations. This study shows the impact of rare functional AKAP9 mutations on Tau, a central mechanism of AD pathogenesis, in LCLs derived from AD and control subjects.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalJournal of NeuroImmune Pharmacology
DOIs
Publication statusAccepted/In press - Mar 7 2018

    Fingerprint

Keywords

  • African American
  • AKAP9
  • Alzheimer disease
  • Amyloid-β peptide
  • APP
  • Rolipram
  • Tau

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this